88 results
8-K
EX-99.1
KALV
KalVista Pharmaceuticals Inc
11 Mar 24
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
4:37pm
. Eligible participants included adolescents, patients using long-term prophylaxis, and the trial evaluated all attack severities and locations … liability - current portion
Total current liabilities
Long-term liabilities:
Lease liability - net of current portion
Total long-term liabilities
8-K
EX-1.1
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
4:32pm
in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend
424B5
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
Prospectus supplement for primary offering
4:29pm
trial ever conducted in HAE, and included adolescents, patients using long-term
S-3
prophylaxis, and all attack severities and locations. Consistent … for people living with HAE and other diseases.
In August 2022, we initiated KONFIDENT-S, a two-year open-label extension trial assessing the long-term safety
424B5
KALV
KalVista Pharmaceuticals Inc
14 Feb 24
Prospectus supplement for primary offering
5:13pm
ever conducted in HAE, and included adolescents, patients using long-term
S-3
prophylaxis, and all attack severities and locations. Consistent … living with HAE and other diseases.
In August 2022, we initiated KONFIDENT-S, a two-year open-label extension trial assessing the long-term safety
8-K
EX-99.2
jgr e1yq8cp6z
13 Feb 24
Regulation FD Disclosure
6:55am
8-K
EX-99.1
58eshp
13 Feb 24
Regulation FD Disclosure
6:55am
8-K
EX-99.1
jn0nxv6py76h k9bo2
7 Dec 23
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
4:17pm
8-K
EX-99.1
svt0bh
7 Sep 23
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
4:35pm
8-K
EX-99.1
basuadk1uqhxvy n4
7 Jul 23
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
7:10pm
424B5
ncvdaqk az111rb4
27 Dec 22
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.1
r6ucn5anmpnmc
8 Dec 22
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
4:13pm
8-K
EX-99.1
7vu89dj3
8 Sep 22
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
4:13pm